Navigation Links
Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
Date:5/19/2008

- RDEA594 Data to Be Presented at the 2008 Annual European Congress of Rheumatology Organized by the European League Against Rheumatism (EULAR) - - Initiation of Phase 1 Human Study of RDEA594 Planned in Second Half of

2008 -

SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the identification of its lead development candidate for the treatment of patients with gout, RDEA594. Gout is a painful and debilitating disease that is caused by abnormally elevated levels of uric acid in the blood stream. RDEA594 is a major metabolite in both humans and animals of RDEA806, the Company's lead human immunodeficiency virus (HIV) development candidate. RDEA594 does not have significant antiviral activity, but is believed to be responsible for essentially all of the uric acid lowering effects seen with RDEA806. Robust uric acid-lowering effects have been observed following administration of RDEA806 in Phase 1 and Phase 2 clinical trials that included over 100 subjects.

Based on extensive in vitro and in vivo experiments, the Company believes it has elucidated the mechanism by which RDEA594 lowers serum uric acid levels. RDEA594 exhibits a concentration-dependent inhibitory effect on the URAT1 transporter-mediated uptake of uric acid ex vivo and increases uric acid excretion in animal models. These effects are believed to result in the lowering of serum uric acid observed with RDEA806. URAT1 is a specific urate transporter expressed in the kidney responsible for regulation of uric acid levels, and is a validated target for treatment of hyperuricemia and gout.

"Gout represents a major medical challenge in the United States and throughout the world,
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
2. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
3. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
4. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
5. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
8. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
9. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
10. Neurocrine Biosciences Reports First Quarter 2008 Results
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...ON, Pa., Nov. 6 In consultation wi...Neil Consumer Healthcare, Division of McNEIL-PPC, ...d number of product lots of TYLENOL® Arthriti...ive red EZ-OPEN CAP. McNeil is initiating the reca...taste associated with these lots that led to a sma...
(Date:11/6/2009)...6 Watson Pharmaceuticals...utical company, announced today that Paul Bisaro, ...ll provide an overview and update of the Company,s...are Conference on Wednesday, November 11, 2009 at ...ation will be webcast live and can be accessed on ...
(Date:11/6/2009)... Roper Industries, Inc. ...a definitive agreement to acquire Verathon, Inc., ... The Verathon Board of Directors has approved the...ry regulatory approvals and closing conditions, in...the closing to be completed in early December. ,...
Breaking Medicine Technology:McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Los Angeles fast food restaurant ban unlikely to cut obesity study finds 58909 1Los Angeles fast food restaurant ban unlikely to cut obesity study finds 58909 2Los Angeles fast food restaurant ban unlikely to cut obesity study finds 58909 3Dentist Office Music Gets A New Sound With Smile Radio 58906 1Dentist Office Music Gets A New Sound With Smile Radio 58906 2HEAL Africas Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 58904 1HEAL Africas Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 58904 2HEAL Africas Founders Conduct Nationwide Tour to Share Best Practices for Rebuilding Congo 58904 3
... 2007 - Results from a new,study, presented at the...ce, showed that more than 99 percent of patients w...were treated,successfully with PEGASYS(R) (peginte...n years later - validating the use of,the word "cu...y,authors. Currently, the best indicator of treatm...
...reatment for People Suffering,from Barrett,s Esoph...GTON, MASSACHUSETTS--(CCNMatthews - May 17, 2007) ...unced that the U.S. Food,and Drug Administration (...an(R) (aminolevulinic acid HCl) Photodynamic Thera.... This disease occurs in,some patients with Barret...
Other Medicine Technology:Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 2Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 3Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 4Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 5Pegasys Study Authors Conclude that Patients Successfully Treated,for Hepatitis C Can be Considered ''Cured'' 6DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan,PDT to Treat Esophage al Dysplasia 2DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan,PDT to Treat Esophage al Dysplasia 3DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan,PDT to Treat Esophage al Dysplasia 4
(Date:11/8/2009)...my of Health holds open house at Victoria campus ...ember 8, 2009 -- UCW Academy of Health invites any...rsquo;s health care industry to attend their open ... , ,UCW Academy of Health, which offers diplomas ...l services, designs its programs to meet the needs...
(Date:11/8/2009)...e-USNewswire/ -- Speaker Nancy Pelosi and Democrat...ouse passage of H.R. 3962, the Affordable Health C... 220 to 215. Below are the Speaker,s opening rema...ived a call from the President of the United State...ory for the American people. I thank the President...
(Date:11/8/2009)... Solutions is pleased to announce that it has been...t for ReSound who recently received an award on th...e award includes not only the Veterans Administrat...federal agencies. , New Y...tions is pleased to announce that it has been succ...
(Date:11/8/2009)... 8 people in the Western District of Pennsylvania ...d suffering for a medical malpractice case. Attor...ra of Thomas E. Crenney and Associates, LLC handle...ersky and against the Uniontown Hospital. The wom...ectomy at age 18. , Pitts...
(Date:11/8/2009)...Hispanic health advocates committed to achieving m...GTON, Nov. 7 "Tonight t...heard the voice of America,s families by passing t... Senate must deliver, without delay, on the promis... L. Delgado, President and CEO of the National All...
Breaking Medicine News(10 mins):Health News:College Invites Public to Explore Career Options in Health Care 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 2Health News:3D Global Solutions Selected to Program Manage GN ReSound/VA Digital Hearing Aid Contract 3Health News:Pennsylvania Jury Awards $2.3 Million to Fayette County Woman in Medical Malpractice Case 2Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2
...hildren,s Hospital Opens,Today, PHILADELPHIA, May...now available for expectant mothers needing highly...ose Family Special,Delivery Unit at The Children,s...w.newscom.com/cgi-bin/prnh/20080520/DC23076 ), "...
...day at the International Conference of the America...ant therapy with Perforomist Inhalation Solution (...livered by nebulization, and Spiriva (tiotropium; ...g-term, twice-daily maintenance treatment of bronc...
...rectors of BD (Becton, Dickinson and Company) (NYS...5 cents per common share. The dividend will be,pay... 9, 2008. The,indicated annual dividend rate is $1...ts, is dedicated to,improving people,s health thro...
...lletin Board: SYMD) announced today that its Board...er rights plan. The shareholder rights plan is,des...ue and equal treatment,in the event of an attempte... a result of any specific takeover attempt., To i...
...nse of competence, study suggests , , TUES...can affect your ability to make sense of what you ...ke-NUS Graduate Medical School in Singapore shows....ear-normal brain function in which they were able ...
...amsey is,holding a Free informational seminar for .... Dr. Ramsey together with Dr. Jessica Marier will...ht differently -- and what,women can do to even ou...8 from 1:00-3:00pm. Please join us for this,intera...
Other Medicine News:Health News:The Children's Hospital of Philadelphia Opens the World's First Delivery Unit for Mothers Diagnosed with Birth Defects in Fetus 2Health News:The Children's Hospital of Philadelphia Opens the World's First Delivery Unit for Mothers Diagnosed with Birth Defects in Fetus 3Health News:The Children's Hospital of Philadelphia Opens the World's First Delivery Unit for Mothers Diagnosed with Birth Defects in Fetus 4Health News:Concomitant use of Perforomist & tiotropium -- significant improvements -- COPD 2Health News:SyntheMed, Inc. Adopts Shareholder Rights Plan 2Health News:Sleep-Deprived Brains Show Lapse in Visual Processing 2
...t two-stage, oil-sealed, rotary vane vacuum pumps ...pplications. Each pump comes complete with a GBORK...ter (EMF-10). The GBORK allows the user to apply f...ng oil. The EMF10 filter the exhaust to keep envir...
...rformance for all vacuum requirements. A 3 positio...o suit all applications. The large, sideview sight...l levels at a glance. The VLP series of pumps is d...ncentrating and freeze drying systems for maximum ...
...et, compact, efficient vacuum source developed spe...e design and TEFLON®/ETFE coated vapor path of...ced maintenance. Unique features include a TEFLON ..., and a 1-liter post-pump solvent recovery vessel ...
...t two-stage, oil-sealed, rotary vane vacuum pumps ...pplications. Each pump comes complete with a GBORK...ter (EMF-10). The GBORK allows the user to apply f...ng oil. The EMF10 filter the exhaust to keep envir...
Medicine Products: